Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone857-242-0170
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees59
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions
What is Magenta Therapeutics' stock symbol?
Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."
How were Magenta Therapeutics' earnings last quarter?
Magenta Therapeutics Inc (NASDAQ:MGTA) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.55) by $0.11. View Magenta Therapeutics' Earnings History.
When is Magenta Therapeutics' next earnings date?
What price target have analysts set for MGTA?
5 brokers have issued 12-month price objectives for Magenta Therapeutics' stock. Their predictions range from $16.00 to $22.00. On average, they anticipate Magenta Therapeutics' stock price to reach $18.6667 in the next year. This suggests a possible upside of 24.9% from the stock's current price. View Analyst Price Targets for Magenta Therapeutics.
What is the consensus analysts' recommendation for Magenta Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Magenta Therapeutics.
Has Magenta Therapeutics been receiving favorable news coverage?
Media coverage about MGTA stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Magenta Therapeutics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Magenta Therapeutics.
Are investors shorting Magenta Therapeutics?
Magenta Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totalling 1,384,400 shares, a drop of 12.0% from the April 15th total of 1,573,500 shares. Based on an average daily trading volume, of 218,000 shares, the days-to-cover ratio is currently 6.4 days. Currently, 5.1% of the shares of the stock are short sold. View Magenta Therapeutics' Current Options Chain.
Who are some of Magenta Therapeutics' key competitors?
Some companies that are related to Magenta Therapeutics include Portola Pharmaceuticals (PTLA), Allakos (ALLK), Zai Lab (ZLAB), Tricida (TCDA), AnaptysBio (ANAB), Pacira Biosciences (PCRX), Enanta Pharmaceuticals (ENTA), Ironwood Pharmaceuticals (IRWD), Biohaven Pharmaceutical (BHVN), Zogenix (ZGNX), Supernus Pharmaceuticals (SUPN), Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL), Nabriva Therapeutics (NBRV) and Cambrex (CBM).
What other stocks do shareholders of Magenta Therapeutics own?
Who are Magenta Therapeutics' key executives?
Magenta Therapeutics' management team includes the folowing people:
- Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 48)
- Mr. Michael P. Cooke, Chief Scientific Officer (Age 57)
- Ms. Alison Lawton, Board Advisor (Age 58)
- Mr. Jason Ryan, Chief Operating & Financial Officer (Age 45)
- Ms. Manisha Pai, VP of Investor Relations & Communications
When did Magenta Therapeutics IPO?
(MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Magenta Therapeutics' major shareholders?
Magenta Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (5.44%), Harvard Management Co. Inc. (0.97%), Spark Investment Management LLC (0.07%), Oppenheimer & Co. Inc. (0.06%), Rhumbline Advisers (0.04%) and Aries Wealth Management (0.04%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, David Scadden, Jason Gardner and Michael P Cooke. View Institutional Ownership Trends for Magenta Therapeutics.
Which major investors are selling Magenta Therapeutics stock?
MGTA stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Harvard Management Co. Inc. and Spark Investment Management LLC. Company insiders that have sold Magenta Therapeutics company stock in the last year include Bruce Booth and Michael P Cooke. View Insider Buying and Selling for Magenta Therapeutics.
Which major investors are buying Magenta Therapeutics stock?
MGTA stock was purchased by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Oppenheimer & Co. Inc., Rhumbline Advisers, Aries Wealth Management and BNP Paribas Arbitrage SA. Company insiders that have bought Magenta Therapeutics stock in the last two years include David Scadden and Jason Gardner. View Insider Buying and Selling for Magenta Therapeutics.
How do I buy shares of Magenta Therapeutics?
Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Magenta Therapeutics' stock price today?
One share of MGTA stock can currently be purchased for approximately $14.94.
How big of a company is Magenta Therapeutics?
Magenta Therapeutics has a market capitalization of $502.78 million. The company earns $-57,510,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe.View Additional Information About Magenta Therapeutics.
What is Magenta Therapeutics' official website?
How can I contact Magenta Therapeutics?
Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]
MarketBeat Community Rating for Magenta Therapeutics (NASDAQ MGTA)
MarketBeat's community ratings are surveys of what our community members think about Magenta Therapeutics and other stocks. Vote "Outperform" if you believe MGTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
